Advertisement
Canada markets closed
  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CAD/USD

    0.7299
    +0.0001 (+0.02%)
     
  • CRUDE OIL

    82.65
    -0.16 (-0.19%)
     
  • Bitcoin CAD

    88,387.41
    -3,099.27 (-3.39%)
     
  • CMC Crypto 200

    1,394.59
    -29.51 (-2.07%)
     
  • GOLD FUTURES

    2,330.30
    -8.10 (-0.35%)
     
  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • NASDAQ futures

    17,486.75
    -177.75 (-1.01%)
     
  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • NIKKEI 225

    38,013.29
    -446.79 (-1.16%)
     
  • CAD/EUR

    0.6819
    0.0000 (0.00%)
     

PerkinElmer and Mallinckrodt Help Bottom Ten Stocks in XLV

XLV's Best and Worst Performers in the Last Week of August

(Continued from Prior Part)

XLV’s bottom ten outperform top ten

Within the Health Care Select Sector SPDR ETF (XLV), the top ten stocks according to market cap underperformed the bottom ten stocks. The bottom ten stocks’ average return was 2.51% for the period between August 25 to August 31. The top ten stocks’ average return was 1.91% for the same period. The bottom ten stocks collectively outperformed the top ten stocks with consistent returns among all ten stocks except Patterson Companies (PDCO), which fell by 4.10%.

The above graph reflects the performance of XLV’s top ten versus the bottom ten for the period between August 25 to August 31.

ADVERTISEMENT

PerkinElmer and Mallinckrodt outperform, while Patterson underperforms

PerkinElmer (PKI) with a return of 5.94% was the best performer of XLV’s bottom ten stocks. The company presented its expertise on its multi-modality imaging solutions at World Molecular Imaging Congress’s annual meeting on September 2 to September 5.

Mallinckrodt Pharmaceuticals (MNK) gained 5.22% on higher trade volumes, as it was in the oversold territory with a relative strength index (or RSI) of 33.

The top ten holdings were supported by Gilead Sciences (GILD) and UnitedHealth Group (UNH) with a return of 4.39% and 4.77%, respectively. GILD published the results from the study of first-line treatment with Letairis and Tadalafil in pulmonary arterial hypertension. The trials were conducted in collaboration with GlaxoSmithKline (GSK).

Continue to Next Part

Browse this series on Market Realist: